Hanlon Sia
About
Hanlon Sia is a scholar working on Hematology, Genetics and Oncology.
According to data from OpenAlex, Hanlon Sia has authored 22 papers receiving a total of 55 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in Hanlon Sia's work include Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Hanlon Sia is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Monoclonal and Polyclonal Antibodies Research (6 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Hanlon Sia collaborates with scholars based in Australia, United States and South Korea. Hanlon Sia's co-authors include Hang Quach, Dorothy H. Crawford, Kenshi Suzuki, Т. С. Константинова, Joseph Mıkhael, Lida Pacaud, Kihyun Kım, Marie‐Laure Risse, Cameron J. McDonald and Tara Cochrane and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
Hanlon Sia
16 papers receiving 54 citations
Peers
Hanlon Sia
Matthew R. Hart United States
Marie Odile Petillon France
Diamond Zuchlinski United States
Johanna Rimpiläinen Finland
Giuseppe Sapienza Italy
Reinoud van Gool Belgium
Asher Chanan-Khan United States
Marta Reinoso Segura Spain
Elisabetta Cretella Italy
Susan Panozzo United States
Citations per year, relative to Hanlon Sia Hanlon Sia (= 1×)
peers
Matthew R. Hart
Countries citing papers authored by Hanlon Sia
Since
Specialization
Citations
This map shows the geographic impact of Hanlon Sia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanlon Sia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanlon Sia more than expected).
Fields of papers citing papers by Hanlon Sia
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hanlon Sia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanlon Sia. The network helps show where Hanlon Sia may publish in the future.
Co-authorship network of co-authors of Hanlon Sia
This figure shows the co-authorship network connecting the top 25 collaborators of Hanlon Sia. A scholar is included among the top collaborators of Hanlon Sia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanlon Sia. Hanlon Sia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Touzeau, Cyrille, Hanlon Sia, Sebastian Grosicki, et al.. (2025). Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial. Blood. 146(Supplement 1). 2283–2283.
2.
Trudel, Suzanne, Hang Quach, Luděk Pour, et al.. (2025). Elranatamab in Combination With Daratumumab and Lenalidomide (EDR) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results from MagnetisMM-6 Part 1. Clinical Lymphoma Myeloma & Leukemia. 25. S5–S5.
3.
Quach, Hang, Amit Khot, Bradley Augustson, et al.. (2025). 554 Pharmacokinetics (PK) and pharmacodynamics (PD) of ISB 2001, a BCMAxCD38xCD3 trispecific antibody, in TRIgnite-1, the first-in-human (FIH) phase 1 study in relapsed/refractory multiple myeloma (RRMM). Regular and Young Investigator Award Abstracts. A633–A634.
4.
Quach, Hang, Vânia Hungria, Luděk Pour, et al.. (2025). Baseline ocular conditions and risk of ocular events in patients (pts) with relapsed/refractory multiple myeloma (RRMM) from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin (belamaf).. Journal of Clinical Oncology. 43(16_suppl). 7544–7544.
5.
Quach, Hang, Bradley Augustson, David Levitz, et al.. (2025). TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results. Clinical Lymphoma Myeloma & Leukemia. 25. S23–S24.
6.
Quach, Hang, Luděk Pour, Sebastian Grosicki, et al.. (2025). MM-1037: Elranatamab (ELRA) in Combination With Daratumumab and Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant: Initial Results From MagnetisMM-6 Part 1. Clinical Lymphoma Myeloma & Leukemia. 25. S956–S956.
7.
Lichtman, Eben I., Amit Khot, Bradley Augustson, et al.. (2025). Phase 1, first-in-human study of ISB 2001: A BCMAxCD38xCD3-targeting trispecific antibody for patients with relapsed/refractory multiple myeloma (RRMM)—Dose escalation (DE) results.. Journal of Clinical Oncology. 43(16_suppl). 7514–7514.
8.
Quach, Hang, Luděk Pour, Sebastian Grosicki, et al.. (2025). Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1.. Journal of Clinical Oncology. 43(16_suppl). 7504–7504.
9.
Quach, Hang, Bradley Augustson, Hanlon Sia, et al.. (2024). First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1026–1026.
10.
Dhakal, Binod, Hang Quach, Andrew Spencer, et al.. (2024). Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3364–3364.
11.
Kremyanskaya, Marina, Lee Ping Chew, Hanlon Sia, et al.. (2024). Initial Results from a Phase 1/2 Study Evaluating Divesiran, a Novel Galnac Conjugated siRNA, in Patients with Polycythemia Vera (SANRECO). Blood. 144(Supplement 1). 656–656.
12.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2024). Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study. Blood Advances. 8(21). 5674–5682.
13.
Verner, Emma, Anna Johnston, Eliza A. Hawkes, et al.. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. Hematological Oncology. 41(S2). 426–427.
14.
Kazandjian, Dickran, Hang Quach, Hanlon Sia, et al.. (2023). Initial Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM). Blood. 142(Supplement 1). 4707–4707.
15.
Sia, Hanlon, Joshua Richter, Tara Cochrane, et al.. (2022). A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 140(Supplement 1). 10182–10184.
16.
Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2022). Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma. Blood Advances. 6(15). 4506–4515.
17.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2021). Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study. Blood. 138(Supplement 1). 304–304.
18.
Martin, Thomas G., Joseph Mıkhael, Roman Hájek, et al.. (2020). Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis. Blood. 136(Supplement 1). 7–8.
19.
King, Liam, Hanlon Sia, & Shailendra Anoopkumar‐Dukie. (2020). Trimethoprim‐sulfamethoxazole as Pneumocystis jiroveci pneumonia prevention in patients undergoing methotrexate therapy for hematological malignancies: A review of the literature. Hematological Oncology. 39(2). 170–175.
20.
McDonald, Cameron J., Gautam Rishi, Daniel F. Wallace, et al.. (2018). Evaluation of a bone morphogenetic protein 6 variant as a cause of iron loading. Human Genomics. 12(1). 23–23.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Matthew R. Hart Breakdown of academic impact, for papers by Marie Odile Petillon Breakdown of academic impact, for papers by Diamond Zuchlinski Breakdown of academic impact, for papers by Johanna Rimpiläinen Breakdown of academic impact, for papers by Giuseppe Sapienza Breakdown of academic impact, for papers by Reinoud van Gool Breakdown of academic impact, for papers by Asher Chanan-Khan Breakdown of academic impact, for papers by Marta Reinoso Segura Breakdown of academic impact, for papers by Elisabetta Cretella Breakdown of academic impact, for papers by Susan Panozzo